Key result
Purified side population stem cells engrafted into cardiac myofibers at a prevalence of approximately 0.02% after myocardial ischemia and reperfusion.
Why the study?
Does transplantation of adult hematopoietic stem cells (SP cells) lead to regeneration of ischemic cardiac muscle and vascular endothelium in mice with myocardial infarction?
Cohort (n=22)
No
Does transplantation of adult hematopoietic stem cells (SP cells) lead to regeneration of ischemic cardiac muscle and vascular endothelium in mice with myocardial infarction?
Effect estimate: null (95% CI null)
Absolute Event Rate: 0.02% vs 0%
p-value: p=null
Adult hematopoietic stem cells (SP cells) can migrate into ischemic cardiac tissue and differentiate into cardiomyocytes and endothelial cells, suggesting a potential therapeutic strategy for myocardial infarction.
Minimal engraftment cautions against clinical translation; leaves open whether refined stem cell strategies can achieve meaningful cardiac repair.
Myocyte loss in the ischemically injured mammalian heart often leads to irreversible deficits in cardiac function. To identify a source of stem cells capable of restoring damaged cardiac tissue, we transplanted highly enriched hematopoietic stem cells, the so-called side population (SP) cells, into lethally irradiated mice subsequently rendered ischemic by coronary artery occlusion for 60 minutes followed by reperfusion. The engrafted SP cells (CD34(-)/low, c-Kit(+), Sca-1(+)) or their progeny migrated into ischemic cardiac muscle and blood vessels, differentiated to cardiomyocytes and endothelial cells, and contributed to the formation of functional tissue. SP cells were purified from Rosa26 transgenic mice, which express lacZ widely. Donor-derived cardiomyocytes were found primarily in the peri-infarct region at a prevalence of around 0.02% and were identified by expression of lacZ and alpha-actinin, and lack of expression of CD45. Donor-derived endothelial cells were identified by expression of lacZ and Flt-1, an endothelial marker shown to be absent on SP cells. Endothelial engraftment was found at a prevalence of around 3.3%, primarily in small vessels adjacent to the infarct. Our results demonstrate the cardiomyogenic potential of hematopoietic stem cells and suggest a therapeutic strategy that eventually could benefit patients with myocardial infarction.
No takes yet. Share an insight, caveat, or question.
Jackson et al. (2001) conducted a cohort in myocardial infarction (n=22). purified side population (SP) cells from bone marrow vs. sham operation was evaluated on Engraftment prevalence of SP cells into cardiac myofibers and endothelial cells (null, 95% CI null, p=null). Purified side population stem cells engrafted into cardiac myofibers at a prevalence of approximately 0.02% after myocardial ischemia and reperfusion.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: